{"protocolSection":{"identificationModule":{"nctId":"NCT03191396","orgStudyIdInfo":{"id":"NN9535-4339"},"secondaryIdInfos":[{"id":"2016-004965-22","type":"REGISTRY","domain":"EudraCT"},{"id":"U1111-1190-5868","type":"OTHER","domain":"World Health Organization (WHO)"},{"id":"2016","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2016"}],"organization":{"fullName":"Novo Nordisk A/S","class":"INDUSTRY"},"briefTitle":"Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes","officialTitle":"Efficacy and Safety of Semaglutide 1.0 mg Once-weekly Versus Liraglutide 1.2 mg Once-daily as add-on to 1-3 Oral Anti-diabetic Drugs (OADs) in Subjects With Type 2 Diabetes","acronym":"SUSTAIN 10"},"statusModule":{"statusVerifiedDate":"2019-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-06-27","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-07-09","type":"ACTUAL"},"completionDateStruct":{"date":"2018-08-13","type":"ACTUAL"},"studyFirstSubmitDate":"2017-06-16","studyFirstSubmitQcDate":"2017-06-16","studyFirstPostDateStruct":{"date":"2017-06-19","type":"ACTUAL"},"resultsFirstSubmitDate":"2019-07-08","resultsFirstSubmitQcDate":"2019-08-23","resultsFirstPostDateStruct":{"date":"2019-08-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-10-02","lastUpdatePostDateStruct":{"date":"2019-10-15","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Novo Nordisk A/S","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"This study is conducted in Europe. The aim of the study is to compare the effect of semaglutide subcutaneous (s.c., under the skin) 1.0 mg once-weekly to liraglutide s.c.1.2 mg once-daily on blood sugar levels after 30 weeks of treatment in people with type 2 diabetes. The study will last approximately 9 months (37 weeks). Each participant will have 7 visits at the clinic and 3 phone calls with the study doctor. At the visits, participants will have a number of tests, for example: general health checks, blood samples, heart and eye checks etc. Participants will also fill in some forms about their health and satisfaction with their diabetes treatment."},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":577,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Semaglutide","type":"EXPERIMENTAL","description":"Half the study participants are randomised to receive semaglutide","interventionNames":["Drug: Semaglutide"]},{"label":"Liraglutide","type":"ACTIVE_COMPARATOR","description":"Half the study participants are randomised to receive liraglutide","interventionNames":["Drug: Liraglutide"]}],"interventions":[{"type":"DRUG","name":"Semaglutide","description":"Dose gradually increased to 1.0 mg, given s.c. (under the skin), once-weekly for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs (tablets), if any","armGroupLabels":["Semaglutide"]},{"type":"DRUG","name":"Liraglutide","description":"Dose gradually increased to 1.2 mg, given s.c. once-daily for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs, if any","armGroupLabels":["Liraglutide"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in HbA1c","description":"Mean change from baseline (week 0) to week 30 in glycosylated haemoglobin (HbA1c) %. The endpoint was evaluated based on the 'on-treatment without rescue medication period' where subjects were considered treated with trial product, but had not yet initiated rescue medication. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"Week 0, week 30"}],"secondaryOutcomes":[{"measure":"Change in Body Weight (kg)","description":"Mean change from baseline (week 0) to week 30 in body weight measured in kilograms. Results are based on the 'on-treatment without rescue medication' observation period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"Week 0, week 30"},{"measure":"Change in Fasting Plasma Glucose (FPG)","description":"Mean change from baseline in fasting plasma glucose measured in mmol/L. Results are based on the 'on-treatment without rescue medication' observation period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"Week 0, week 30"},{"measure":"Change in Self-measured Plasma Glucose (SMPG), 7 Point Profile: Mean 7-point Profile","description":"Mean change from baseline in 7-point profile. SMPG was recorded at the following 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after dinner and at bedtime. The mean of the 7-point SMPG profile, defined as the area under the profile, was calculated using the trapezoidal method and divided by the measurement time. Results are based on the 'on-treatment without rescue medication' observation period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"Week 0, week 30"},{"measure":"Change in Self-measured Plasma Glucose (SMPG), 7 Point Profile: Mean Post Prandial Increment (Over All Meals)","description":"Mean post prandial glucose incrememts over all meals. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"Week 0, week 30"},{"measure":"Change in Fasting Blood Lipids: Total Cholesterol","description":"The change from baseline in total cholesterol (measured in mmol/L) is presented as ratio to baseline. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"Week 0, week 30"},{"measure":"Change in Fasting Blood Lipids: Low-density Lipoprotein (LDL)-Cholesterol","description":"The change from baseline in LDL cholesterol is presented as ratio to baseline. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"Week 0, week 30"},{"measure":"Change in Fasting Blood Lipids: High-density Lipoprotein (HDL)-Cholesterol","description":"The change from baseline in HDL cholesterol is presented as ratio to baseline. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"Week 0, week 30"},{"measure":"Change in Fasting Blood Lipids: Triglycerides","description":"The change from baseline in triglycerides is presented as ratio to baseline. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"Week 0, week 30"},{"measure":"Change in Body Mass Index (BMI)","description":"Mean change from baseline (week 0) to week 30 in BMI. BMI was calculated as 'body weight in kg/(height in meters) x (height in meters)'. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"Week 0, week 30"},{"measure":"Change in Waist Circumference","description":"Mean change in waist circumference (cm) from baseline (week 0) to week 30. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"Week 0, week 30"},{"measure":"Change in Systolic Blood Pressure","description":"Change in systolic blood pressure from baseline (week 0) to week 30 . Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"Week 0, week 30"},{"measure":"Change in Diastolic Blood Pressure","description":"Change in diastolic blood pressure from baseline (week 0) to week 30 . Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"Week 0, week 30"},{"measure":"Change in Body Weight (%)","description":"Mean relative change from baseline in body weight measured in percentage. Results are based on the 'on-treatment without rescue medication' observation period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"Week 0, week 30"},{"measure":"Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol), American Diabetes Association (ADA) Target","description":"Percentage of subjects who achieved HbA1c less than 7.0% (53 mmol/mol) according to American Diabetes Association (ADA) target, after 30 weeks of treatment. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"After 30 weeks of treatment"},{"measure":"Subjects Who Achieve HbA1c Below or Equal to 6.5% (48 mmol/Mol), American Association of Clinical Endocrinologists (AACE) Target","description":"Percentage of subjects who achieved HbA1c less than 6.5% (48 mmol/mol) according to AACE target,after 30 weeks of treatment. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"After 30 weeks of treatment"},{"measure":"Subjects Who Achieve Weight Loss Above or Equal to 3%","description":"Percentage of subjects who achieved weight loss above or equal to 3% after 30 weeks of treatment. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"After 30 weeks of treatment"},{"measure":"Subjects Who Achieve Weight Loss Above or Equal to 5%","description":"Percentage of subjects who achieved weight loss above or equal to 5% after 30 weeks of treatment. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"After 30 weeks of treatment"},{"measure":"Subjects Who Achieve Weight Loss Above or Equal to 10%","description":"Percentage of subjects who achieved weight loss above or equal to 10% after 30 weeks of treatment. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"After 30 weeks of treatment"},{"measure":"Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol) Without Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemia Episodes and no Weight Gain","description":"Percentage of subjects who achieved HbA1c below 7.0% (53 mmol/mol) without severe or blood glucose confirmed symptomatic hypoglycaemia episodes and no weight gain, after 30 weeks of treatment. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"After 30 weeks of treatment"},{"measure":"Subjects Who Achieve HbA1c Reduction Above or Equal to 1%","description":"Percentage of subjects who achieved weight loss above or equal to 1% after 30 weeks of treatment. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"After 30 weeks of treatment"},{"measure":"Subjects Who Achieve HbA1c Reduction Above or Equal to 1% and Weight Loss Above or Equal to 3%","description":"Percentage of subjects who achieved HbA1c reduction above or equal to 1% and weight loss above or equal to 3% after 30 weeks of treatment. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"After 30 weeks of treatment"},{"measure":"Subjects Who Achieve HbA1c Reduction Above or Equal to 1% and Weight Loss Above or Equal to 5%","description":"Percentage of subjects who achieved HbA1c reduction above or equal to 1% and weight loss above or equal to 5% after 30 weeks of treatment. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"After 30 weeks of treatment"},{"measure":"Subjects Who Achieve HbA1c Reduction Above or Equal to 1% and Weight Loss Above or Equal to 10%","description":"Percentage of subjects who achieved HbA1c reduction above or equal to 1% and weight loss above or equal to 10% after 30 weeks of treatment. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"After 30 weeks of treatment"},{"measure":"Change in SF-36v2 Short Form Health Survey. Total Summary Scores (Physical Component and Mental Component) and Scores From the 8 Domains","description":"Short form-36 version 2 (SF-36v2) is a 36-item patient-reported survey of patient health that measures the subject's overall health-related quality of life (HRQoL). The questionnaire measures the individual overall HRQoL on 8 domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health. Each domain is scored using the sum of the individual item responses and normalised relative to the 2009 US reference population. Overall, the domain scores range from around 0-100 (higher scores indicated a better HRQoL), where the range of possible scores depends on the 2009 US reference population for each domain. The two total summary scores (mental and physical summary components) are calculated through weighted sums of the 8 domain scores. The presented result is the change from baseline (week 0) to week 30 in SF-36v2 scores. A positive change in score indicates an improvement since baseline.","timeFrame":"Week 0, week 30"},{"measure":"Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ). Treatment Satisfaction Summary Score (Sum of 6 of 8 Items) and the 8 Items Separately","description":"The DTSQs questionnaire was used to assess subject's treatment satisfaction. This instrument contains 8 items and measures the treatment for diabetes in terms of convenience, flexibility and general feelings regarding treatment. Q 1 = \"satisfaction with current treatment\"; Q 2 = \"hyperglycemia\"; Q 3 = \"hypoglycemia\"; Q 4 = \"flexibility\"; Q 5 = \"convenience\"; Q 6 = \"understanding of diabetes\"; Q 7 = \"recommend treatment to others\"; and Q 8 = \"willingness to continue\". Each item is rated on a 7-point Likert scale with a score ranging from 0 (ie, very dissatisfied) to 6 (ie, very satisfied). DTSQ items 2 and 3 are rated differently: 0 reflects 'never' and 6 reflects 'most of the time'. The 'treatment satisfaction' score is the sum of 6 of the 8 DTSQs components (Q 1, 4, 5, 6, 7 and 8) (range 0-36). Higher scores on the DTSQ total score indicate higher treatment satisfaction. The results presented is the change from baseline (week 0) to week 30 in DTSQ scores.","timeFrame":"Week 0, week 30"},{"measure":"Number of Treatment-emergent Adverse Events (TEAE)","description":"A TEAE was defined as an adverse event with onset date (or increase in severity) during the on-treatment observation period. The on-treatment observation period represents the time period where subjects were considered exposed to trial product.","timeFrame":"Week 0 to week 35"},{"measure":"Number of Treatment-emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes","description":"Hypoglycaemic episodes were defined as treatment emergent if the onset of the episode occurred within the on-treatment observation period, where the subjects were exposed to the trial product. Severe or BG-confirmed symptomatic hypoglycaemia: an episode that was severe according to the ADA classification or blood glucose confirmed by a plasma glucose value below 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.","timeFrame":"Week 0 to week 35"},{"measure":"Treatment-emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemia Episodes","description":"Number of subjects with treatment-emergent severe or blood glucose confirmed symptomatic hypoglycaemia episodes is presented. Hypoglycaemic episodes were defined as treatment emergent if the onset of the episode occurred within the on-treatment observation period, where the subjects were exposed to the trial product. Severe or BG-confirmed symptomatic hypoglycaemia: an episode that was severe according to the ADA classification or blood glucose confirmed by a plasma glucose value below 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.","timeFrame":"Week 0 to week 35"},{"measure":"Change in Haematology - Haemoglobin","description":"Mean change from baseline (week 0) to week 30 in haemoglobin. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","timeFrame":"Week 0, week 30"},{"measure":"Change in Haematology - Haematocrit","description":"Mean change from baseline (week 0) to week 30 in haematology laboratory parameter haematocrit. Haematocrit is the volume of red blood cells in the total blood. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","timeFrame":"Week 0, week 30"},{"measure":"Change in Haematology - Thrombocytes and Leukocytes","description":"Mean change from baseline (week 0) to week 30 in haematology laboratory parameters thrombocytes and leukocytes. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","timeFrame":"Week 0, week 30"},{"measure":"Change in Haematology - Erythrocytes","description":"Mean change from baseline (week 0) to week 30 in haematology laboratory parameter erythrocytes. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","timeFrame":"Week 0, week 30"},{"measure":"Change in Biochemistry - Calcium, Pottassium and Sodium","description":"Mean change from baseline (week 0) to week 30 in biochemistry laboratory parameters calcium, pottassium and sodium. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","timeFrame":"Week 0, week 30"},{"measure":"Change in Biochemistry - Alkaline Phosphatase, Alanine Aminotransferase and Aspartate Aminotransferase.","description":"Mean change from baseline (week 0) to week 30 in biochemistry laboratory parameters alkaline phosphatase, alanine aminotransferase and aspartate aminotransferase. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","timeFrame":"Week 0, week 30"},{"measure":"Change in Biochemistry - Amylase and Lipase","description":"Mean change from baseline (week 0) to week 30 in biochemistry laboratory parameters amylase and lypase. Observed data with multiple imputation for missing data is presented. Missing data were imputed using observed data from subjects within the same group defined by actual treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","timeFrame":"Week 0, week 30"},{"measure":"Change in Biochemistry - Creatinine and Bilirubin","description":"Mean change from baseline (week 0) to week 30 in biochemistry laboratory parameters creatinine and bilirubin. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","timeFrame":"Week 0, week 30"},{"measure":"Change in Biochemistry - Albumin","description":"Mean change from baseline (week 0) to week 30 in biochemistry laboratory parameter albumin. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","timeFrame":"Week 0, week 30"},{"measure":"Change in Biochemistry - Estimated Glomerular Filtration Rate (eGFR).","description":"Mean change from baseline (week 0) to week 30 in biochemistry laboratory parameter eGFR. eGFR is calculated using the equation from the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) as defined in KDIGO guidelines. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","timeFrame":"Week 0, week 30"},{"measure":"Change in Calcitonin","description":"Mean change from baseline (week 0) to week 30 in calcitonin. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","timeFrame":"Week 0, week 30"},{"measure":"Change in Pulse Rate","description":"Mean change from baseline (week 0) to week 30 in pulse rate. Pulse rate is measured as number of heart beats per minute. Results are based on the on-treatment observation period where subjects were considered exposed to trial product. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","timeFrame":"Week 0, week 30"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria: - Male or female, age 18 years or older at the time of signing informed consent - Diagnosed with type 2 diabetes mellitus - HbA1c of 7.0-11.0 % (53 - 97 mmol/mol) (both inclusive) - Stable daily dose(s) including any of the following anti-diabetic drug(s) or combination regimens 90 days prior to the day of screening: a) Biguanides (metformin above or equal to 1500 mg or maximum tolerated dose documented in the subject's medical record). b) Sulphonylureas (above or equal to half of the maximum approved dose according to local label or maximum tolerated dose as documented in subject medical record). c) SGLT-2 inhibitors (above or equal to half of the maximum approved dose according to local label or maximum tolerated dose as documented in subject medical record) Exclusion Criteria: - Family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma. Family is defined as a first degree relative - History or presence of pancreatitis (acute or chronic) - History of diabetic ketoacidosis - Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening - Subjects presently classified as being in New York Heart Association (NYHA) Class IV - Planned coronary, carotid or peripheral artery revascularisation known on the day of screening - Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of below 30 ml/min/1.73 sqm as defined by KDIGO 2012 classification - Impaired liver function, defined as ALT above or equal to 2.5 times upper normal limit at screening - Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus photography or dilated fundoscopy performed within the past 90 days prior to randomisation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Global Clinical Registry (GCR, 1452)","affiliation":"Novo Nordisk A/S","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Novo Nordisk Investigational Site","city":"Burgas","zip":"8000","country":"Bulgaria","geoPoint":{"lat":42.50651,"lon":27.46886}},{"facility":"Novo Nordisk Investigational Site","city":"Dupnitsa","zip":"2600","country":"Bulgaria","geoPoint":{"lat":42.26478,"lon":23.11723}},{"facility":"Novo Nordisk Investigational Site","city":"Lukovit","zip":"5770","country":"Bulgaria","geoPoint":{"lat":43.2,"lon":24.16667}},{"facility":"Novo Nordisk Investigational Site","city":"Madan","zip":"4900","country":"Bulgaria","geoPoint":{"lat":41.49869,"lon":24.93973}},{"facility":"Novo Nordisk Investigational Site","city":"Petrich","zip":"2850","country":"Bulgaria","geoPoint":{"lat":41.39365,"lon":23.20012}},{"facility":"Novo Nordisk Investigational Site","city":"Rousse","zip":"7000","country":"Bulgaria","geoPoint":{"lat":43.84872,"lon":25.9534}},{"facility":"Novo Nordisk Investigational Site","city":"Sliven","zip":"8800","country":"Bulgaria","geoPoint":{"lat":42.68607,"lon":26.32558}},{"facility":"Novo Nordisk Investigational Site","city":"Sofia","zip":"1606","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Novo Nordisk Investigational Site","city":"Vratsa","zip":"3001","country":"Bulgaria","geoPoint":{"lat":43.21052,"lon":23.56312}},{"facility":"Novo Nordisk Investigational Site","city":"Brno","zip":"602 00","country":"Czechia","geoPoint":{"lat":49.19522,"lon":16.60796}},{"facility":"Novo Nordisk Investigational Site","city":"Brno","zip":"65691","country":"Czechia","geoPoint":{"lat":49.19522,"lon":16.60796}},{"facility":"Novo Nordisk Investigational Site","city":"Náchod","zip":"547 01","country":"Czechia","geoPoint":{"lat":50.4167,"lon":16.16289}},{"facility":"Novo Nordisk Investigational Site","city":"Prague","zip":"100 00","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Novo Nordisk Investigational Site","city":"Prague","zip":"140 46","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Novo Nordisk Investigational Site","city":"Helsinki","zip":"00180","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"Novo Nordisk Investigational Site","city":"Jyväskylä","zip":"40100","country":"Finland","geoPoint":{"lat":62.24147,"lon":25.72088}},{"facility":"Novo Nordisk Investigational Site","city":"Kuusamo","zip":"93600","country":"Finland","geoPoint":{"lat":65.96447,"lon":29.18878}},{"facility":"Novo Nordisk Investigational Site","city":"Lahti","zip":"15110","country":"Finland","geoPoint":{"lat":60.98267,"lon":25.66151}},{"facility":"Novo Nordisk Investigational Site","city":"Oulu","zip":"90220","country":"Finland","geoPoint":{"lat":65.01236,"lon":25.46816}},{"facility":"Novo Nordisk Investigational Site","city":"Rauma","zip":"26100","country":"Finland","geoPoint":{"lat":61.12724,"lon":21.51127}},{"facility":"Novo Nordisk Investigational Site","city":"Turku","zip":"20100","country":"Finland","geoPoint":{"lat":60.45148,"lon":22.26869}},{"facility":"Novo Nordisk Investigational Site","city":"Varkaus","zip":"78300","country":"Finland","geoPoint":{"lat":62.31533,"lon":27.873}},{"facility":"Novo Nordisk Investigational Site","city":"Béziers","zip":"34500","country":"France","geoPoint":{"lat":43.34122,"lon":3.21402}},{"facility":"Novo Nordisk Investigational Site","city":"Dambach-la-Ville","zip":"67650","country":"France","geoPoint":{"lat":48.32379,"lon":7.42547}},{"facility":"Novo Nordisk Investigational Site","city":"Dijon","zip":"21079","country":"France","geoPoint":{"lat":47.31344,"lon":5.01391}},{"facility":"Novo Nordisk Investigational Site","city":"La Rochelle","zip":"17019","country":"France","geoPoint":{"lat":46.16308,"lon":-1.15222}},{"facility":"Novo Nordisk Investigational Site","city":"Le Coudray","zip":"28630","country":"France","geoPoint":{"lat":48.42115,"lon":1.50057}},{"facility":"Novo Nordisk Investigational Site","city":"Le Creusot","zip":"71200","country":"France","geoPoint":{"lat":46.80714,"lon":4.41632}},{"facility":"Novo Nordisk Investigational Site","city":"Nantes","zip":"44200","country":"France","geoPoint":{"lat":47.21725,"lon":-1.55336}},{"facility":"Novo Nordisk Investigational Site","city":"Obernai","zip":"67210","country":"France","geoPoint":{"lat":48.46313,"lon":7.481}},{"facility":"Novo Nordisk Investigational Site","city":"Paris","zip":"75010","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Novo Nordisk Investigational Site","city":"Paris","zip":"75877","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Novo Nordisk Investigational Site","city":"Perpignan","zip":"66046","country":"France","geoPoint":{"lat":42.69764,"lon":2.89541}},{"facility":"Novo Nordisk Investigational Site","city":"Schiltigheim","zip":"67300","country":"France","geoPoint":{"lat":48.60749,"lon":7.74931}},{"facility":"Novo Nordisk Investigational Site","city":"Strasbourg","zip":"67000","country":"France","geoPoint":{"lat":48.58392,"lon":7.74553}},{"facility":"Novo Nordisk Investigational Site","city":"Vandœuvre-lès-Nancy","zip":"54511","country":"France","geoPoint":{"lat":48.66115,"lon":6.17114}},{"facility":"Novo Nordisk Investigational Site","city":"Vénissieux","zip":"69200","country":"France","geoPoint":{"lat":45.69706,"lon":4.88593}},{"facility":"Novo Nordisk Investigational Site","city":"Dresden","zip":"01219","country":"Germany","geoPoint":{"lat":51.05089,"lon":13.73832}},{"facility":"Novo Nordisk Investigational Site","city":"Essen","zip":"45136","country":"Germany","geoPoint":{"lat":51.45657,"lon":7.01228}},{"facility":"Novo Nordisk Investigational Site","city":"Falkensee","zip":"14612","country":"Germany","geoPoint":{"lat":52.56014,"lon":13.0927}},{"facility":"Novo Nordisk Investigational Site","city":"Hamburg","zip":"22607","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"Novo Nordisk Investigational Site","city":"Saint Ingbert-Oberwürzbach","zip":"66386","country":"Germany"},{"facility":"Novo Nordisk Investigational Site","city":"Stuttgart","zip":"70378","country":"Germany","geoPoint":{"lat":48.78232,"lon":9.17702}},{"facility":"Novo Nordisk Investigational Site","city":"Budapest","zip":"1033","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Novo Nordisk Investigational Site","city":"Budapest","zip":"1125","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Novo Nordisk Investigational Site","city":"Nagykanizsa","zip":"8800","country":"Hungary","geoPoint":{"lat":46.45347,"lon":16.99104}},{"facility":"Novo Nordisk Investigational Site","city":"Pécs","zip":"7623","country":"Hungary","geoPoint":{"lat":46.07617,"lon":18.22814}},{"facility":"Novo Nordisk Investigational Site","city":"Siófok","zip":"8600","country":"Hungary","geoPoint":{"lat":46.90413,"lon":18.058}},{"facility":"Novo Nordisk Investigational Site","city":"Szolnok","zip":"5004","country":"Hungary","geoPoint":{"lat":47.18066,"lon":20.19835}},{"facility":"Novo Nordisk Investigational Site","city":"Tatabánya","zip":"2800","country":"Hungary","geoPoint":{"lat":47.59247,"lon":18.38099}},{"facility":"Novo Nordisk Investigational Site","city":"Zalaegerszeg","zip":"8900","country":"Hungary","geoPoint":{"lat":46.83695,"lon":16.84401}},{"facility":"Novo Nordisk Investigational Site","city":"Bergamo","zip":"24127","country":"Italy","geoPoint":{"lat":45.69601,"lon":9.66721}},{"facility":"Novo Nordisk Investigational Site","city":"Como","zip":"22042","country":"Italy","geoPoint":{"lat":45.80819,"lon":9.0832}},{"facility":"Novo Nordisk Investigational Site","city":"Milan","zip":"20132","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Novo Nordisk Investigational Site","city":"Pavia","zip":"27100","country":"Italy","geoPoint":{"lat":45.19205,"lon":9.15917}},{"facility":"Novo Nordisk Investigational Site","city":"Rome","zip":"00168","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"Novo Nordisk Investigational Site","city":"Lublin","zip":"20-044","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"Novo Nordisk Investigational Site","city":"Lublin","zip":"20-538","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"Novo Nordisk Investigational Site","city":"Szczecin","zip":"70-506","country":"Poland","geoPoint":{"lat":53.42894,"lon":14.55302}},{"facility":"Novo Nordisk Investigational Site","city":"Celje","zip":"SI-3000","country":"Slovenia","geoPoint":{"lat":46.23092,"lon":15.26044}},{"facility":"Novo Nordisk Investigational Site","city":"Jesenice","zip":"SI-4270","country":"Slovenia","geoPoint":{"lat":46.4324,"lon":14.06232}},{"facility":"Novo Nordisk Investigational Site","city":"Koper","zip":"SI-6000","country":"Slovenia","geoPoint":{"lat":45.5482,"lon":13.72963}},{"facility":"Novo Nordisk Investigational Site","city":"Ljubljana","zip":"1525","country":"Slovenia","geoPoint":{"lat":46.05108,"lon":14.50513}},{"facility":"Novo Nordisk Investigational Site","city":"Alcorcón","zip":"28922","country":"Spain","geoPoint":{"lat":40.34582,"lon":-3.82487}},{"facility":"Novo Nordisk Investigational Site","city":"Almería","zip":"04001","country":"Spain","geoPoint":{"lat":36.83814,"lon":-2.45974}},{"facility":"Novo Nordisk Investigational Site","city":"La Roca Del Vallés","zip":"08430","country":"Spain"},{"facility":"Novo Nordisk Investigational Site","city":"Palma de Mallorca","zip":"07014","country":"Spain","geoPoint":{"lat":39.56939,"lon":2.65024}},{"facility":"Novo Nordisk Investigational Site","city":"Valladolid","zip":"47010","country":"Spain","geoPoint":{"lat":41.65541,"lon":-4.72353}},{"facility":"Novo Nordisk Investigational Site","city":"Vic (Barcelona)","zip":"08500","country":"Spain","geoPoint":{"lat":41.93012,"lon":2.25486}},{"facility":"Novo Nordisk Investigational Site","city":"Ängelholm","zip":"262 81","country":"Sweden","geoPoint":{"lat":56.2428,"lon":12.86219}},{"facility":"Novo Nordisk Investigational Site","city":"Kristianstad","zip":"291 85","country":"Sweden","geoPoint":{"lat":56.03129,"lon":14.15242}},{"facility":"Novo Nordisk Investigational Site","city":"Lund","zip":"222 22","country":"Sweden","geoPoint":{"lat":55.70584,"lon":13.19321}},{"facility":"Novo Nordisk Investigational Site","city":"Örebro","zip":"701 85","country":"Sweden","geoPoint":{"lat":59.27412,"lon":15.2066}},{"facility":"Novo Nordisk Investigational Site","city":"Stockholm","zip":"112 81","country":"Sweden","geoPoint":{"lat":59.32938,"lon":18.06871}},{"facility":"Novo Nordisk Investigational Site","city":"Stockholm","zip":"171 76","country":"Sweden","geoPoint":{"lat":59.32938,"lon":18.06871}},{"facility":"Novo Nordisk Investigational Site","city":"Blackpool","zip":"FY3 7EN","country":"United Kingdom","geoPoint":{"lat":53.81667,"lon":-3.05}},{"facility":"Novo Nordisk Investigational Site","city":"Bristol","zip":"BS10 5NB","country":"United Kingdom","geoPoint":{"lat":51.45523,"lon":-2.59665}},{"facility":"Novo Nordisk Investigational Site","city":"Coventry","zip":"CV2 2DX","country":"United Kingdom","geoPoint":{"lat":52.40656,"lon":-1.51217}},{"facility":"Novo Nordisk Investigational Site","city":"Crewe","zip":"CW5 5NX","country":"United Kingdom","geoPoint":{"lat":53.09787,"lon":-2.44161}},{"facility":"Novo Nordisk Investigational Site","city":"Faringdon","zip":"SN7 7YU.","country":"United Kingdom","geoPoint":{"lat":51.65644,"lon":-1.58676}},{"facility":"Novo Nordisk Investigational Site","city":"Hinckley","zip":"LE10 2SE","country":"United Kingdom","geoPoint":{"lat":52.5389,"lon":-1.37613}},{"facility":"Novo Nordisk Investigational Site","city":"London","zip":"SW17 0QT","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Novo Nordisk Investigational Site","city":"Northwood","zip":"HA6 2RN","country":"United Kingdom","geoPoint":{"lat":51.61162,"lon":-0.42454}},{"facility":"Novo Nordisk Investigational Site","city":"Norwich","zip":"NR4 7TJ","country":"United Kingdom","geoPoint":{"lat":52.62783,"lon":1.29834}},{"facility":"Novo Nordisk Investigational Site","city":"Nuneaton","zip":"CV10 7DJ","country":"United Kingdom","geoPoint":{"lat":52.52323,"lon":-1.46523}},{"facility":"Novo Nordisk Investigational Site","city":"Rhyl","zip":"LL18 1DA","country":"United Kingdom","geoPoint":{"lat":53.31929,"lon":-3.49228}},{"facility":"Novo Nordisk Investigational Site","city":"Rotherham","zip":"S65 1DA","country":"United Kingdom","geoPoint":{"lat":53.43012,"lon":-1.35678}},{"facility":"Novo Nordisk Investigational Site","city":"Sidcup","zip":"DA14 6LT","country":"United Kingdom","geoPoint":{"lat":51.42619,"lon":0.1036}},{"facility":"Novo Nordisk Investigational Site","city":"Southampton","zip":"SO30 3JB","country":"United Kingdom","geoPoint":{"lat":50.90395,"lon":-1.40428}},{"facility":"Novo Nordisk Investigational Site","city":"St Helens","zip":"WA9 3DA","country":"United Kingdom","geoPoint":{"lat":53.45,"lon":-2.73333}},{"facility":"Novo Nordisk Investigational Site","city":"Truro","zip":"TR1 3LJ","country":"United Kingdom","geoPoint":{"lat":50.26526,"lon":-5.05436}},{"facility":"Novo Nordisk Investigational Site","city":"Watford","zip":"WD25 7NL","country":"United Kingdom","geoPoint":{"lat":51.65531,"lon":-0.39602}}]},"referencesModule":{"references":[{"pmid":"31539622","type":"RESULT","citation":"Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, Verges B, Marre M. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020 Apr;46(2):100-109. doi: 10.1016/j.diabet.2019.101117. Epub 2019 Sep 17."},{"pmid":"32193837","type":"DERIVED","citation":"Capehorn M, Ghani Y, Hindsberger C, Johansen P, Jodar E. Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10. Diabetes Ther. 2020 May;11(5):1061-1075. doi: 10.1007/s13300-020-00796-z. Epub 2020 Mar 19."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"According to the Novo Nordisk disclosure commitment on novonordisk-trials.com"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"After screening, subjects were required to continue their oral anti-diabetic drug (OAD) pre-trial background medication (i.e. metformin, Sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulphonyl ureas, or combinations of these) throughout the entire trial.","recruitmentDetails":"The trial was conducted at 77 sites in 11 countries as follows (number of sites that screened subjects/ number of sites that randomised subjects):\n\nBulgaria (9/ 9); Czech Republic (5/ 5); Finland (8/ 8); France (8/ 8); Hungary (8/ 8); Italy (4/ 4); Poland (3/ 3); Slovenia (4/ 4); Spain (5/ 5); Sweden (6/ 6); United Kingdom (17/ 17)","groups":[{"id":"FG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"FG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"290"},{"groupId":"FG001","numSubjects":"287"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"287"},{"groupId":"FG001","numSubjects":"282"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"5"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"BG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"290"},{"groupId":"BG001","value":"287"},{"groupId":"BG002","value":"577"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60.1","spread":"10.5"},{"groupId":"BG001","value":"58.9","spread":"10.0"},{"groupId":"BG002","value":"59.5","spread":"10.2"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"130"},{"groupId":"BG001","value":"120"},{"groupId":"BG002","value":"250"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"160"},{"groupId":"BG001","value":"167"},{"groupId":"BG002","value":"327"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"9"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"268"},{"groupId":"BG001","value":"269"},{"groupId":"BG002","value":"537"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"31"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"8"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"264"},{"groupId":"BG001","value":"268"},{"groupId":"BG002","value":"532"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"31"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c","description":"Mean change from baseline (week 0) to week 30 in glycosylated haemoglobin (HbA1c) %. The endpoint was evaluated based on the 'on-treatment without rescue medication period' where subjects were considered treated with trial product, but had not yet initiated rescue medication. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage of glycosylated haemoglobin","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"0.9"},{"groupId":"OG001","value":"-1.1","spread":"1.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The responses are analysed using an ANCOVA with treatment and stratification factor as fixed factors and baseline value as covariate. Before analysis, missing data were multiple imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"HbA1c non-inferiority was tested using a non-inferiority margin of 0.3.","pValue":"<0.0001","pValueComment":"The non-inferiority p-value is calculated as two times the one-sided p-value from a t-distributed test statistic comparing the treatment contrast with 0.3.","statisticalMethod":"ANCOVA","paramType":"Treatment difference","paramValue":"-0.69","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.82","ciUpperLimit":"-0.56","estimateComment":"Semaglutide 1.0 mg - Liraglutide 1.2 mg"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"ANCOVA","paramType":"Treatment difference","paramValue":"-0.69","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.82","ciUpperLimit":"-0.56","estimateComment":"Semaglutide 1.0 mg - Liraglutide 1.2 mg"}]},{"type":"SECONDARY","title":"Change in Body Weight (kg)","description":"Mean change from baseline (week 0) to week 30 in body weight measured in kilograms. Results are based on the 'on-treatment without rescue medication' observation period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"kg","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.8","spread":"4.7"},{"groupId":"OG001","value":"-2.0","spread":"4.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"ANCOVA","paramType":"Treatment difference","paramValue":"-3.83","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.57","ciUpperLimit":"-3.09","estimateComment":"Semaglutide 1.0 mg - Liraglutide 1.2 mg"}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG)","description":"Mean change from baseline in fasting plasma glucose measured in mmol/L. Results are based on the 'on-treatment without rescue medication' observation period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.65","spread":"2.19"},{"groupId":"OG001","value":"-1.46","spread":"2.42"}]}]}]},{"type":"SECONDARY","title":"Change in Self-measured Plasma Glucose (SMPG), 7 Point Profile: Mean 7-point Profile","description":"Mean change from baseline in 7-point profile. SMPG was recorded at the following 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after dinner and at bedtime. The mean of the 7-point SMPG profile, defined as the area under the profile, was calculated using the trapezoidal method and divided by the measurement time. Results are based on the 'on-treatment without rescue medication' observation period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":"2.0"},{"groupId":"OG001","value":"-2.1","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Change in Self-measured Plasma Glucose (SMPG), 7 Point Profile: Mean Post Prandial Increment (Over All Meals)","description":"Mean post prandial glucose incrememts over all meals. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"1.8"},{"groupId":"OG001","value":"-0.4","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Blood Lipids: Total Cholesterol","description":"The change from baseline in total cholesterol (measured in mmol/L) is presented as ratio to baseline. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ratio","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"16.8"},{"groupId":"OG001","value":"0.98","spread":"16.9"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Blood Lipids: Low-density Lipoprotein (LDL)-Cholesterol","description":"The change from baseline in LDL cholesterol is presented as ratio to baseline. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ratio","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"28.3"},{"groupId":"OG001","value":"0.99","spread":"27.2"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Blood Lipids: High-density Lipoprotein (HDL)-Cholesterol","description":"The change from baseline in HDL cholesterol is presented as ratio to baseline. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ratio","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":"14.6"},{"groupId":"OG001","value":"0.99","spread":"12.9"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Blood Lipids: Triglycerides","description":"The change from baseline in triglycerides is presented as ratio to baseline. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"41.5"},{"groupId":"OG001","value":"0.91","spread":"39.5"}]}]}]},{"type":"SECONDARY","title":"Change in Body Mass Index (BMI)","description":"Mean change from baseline (week 0) to week 30 in BMI. BMI was calculated as 'body weight in kg/(height in meters) x (height in meters)'. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"kg/sqm","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"1.6"},{"groupId":"OG001","value":"-0.7","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Change in Waist Circumference","description":"Mean change in waist circumference (cm) from baseline (week 0) to week 30. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"cm","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.2","spread":"5.6"},{"groupId":"OG001","value":"-2.4","spread":"4.6"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure","description":"Change in systolic blood pressure from baseline (week 0) to week 30 . Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmHg","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.3","spread":"13.4"},{"groupId":"OG001","value":"-3.7","spread":"13.8"}]}]}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure","description":"Change in diastolic blood pressure from baseline (week 0) to week 30 . Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmHg","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"8.6"},{"groupId":"OG001","value":"-1.3","spread":"8.4"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight (%)","description":"Mean relative change from baseline in body weight measured in percentage. Results are based on the 'on-treatment without rescue medication' observation period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage of body weight","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.1","spread":"4.9"},{"groupId":"OG001","value":"-2.0","spread":"4.2"}]}]}]},{"type":"SECONDARY","title":"Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol), American Diabetes Association (ADA) Target","description":"Percentage of subjects who achieved HbA1c less than 7.0% (53 mmol/mol) according to American Diabetes Association (ADA) target, after 30 weeks of treatment. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"After 30 weeks of treatment","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.4"},{"groupId":"OG001","value":"45.9"}]}]}]},{"type":"SECONDARY","title":"Subjects Who Achieve HbA1c Below or Equal to 6.5% (48 mmol/Mol), American Association of Clinical Endocrinologists (AACE) Target","description":"Percentage of subjects who achieved HbA1c less than 6.5% (48 mmol/mol) according to AACE target,after 30 weeks of treatment. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"After 30 weeks of treatment","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.5"},{"groupId":"OG001","value":"24.8"}]}]}]},{"type":"SECONDARY","title":"Subjects Who Achieve Weight Loss Above or Equal to 3%","description":"Percentage of subjects who achieved weight loss above or equal to 3% after 30 weeks of treatment. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"After 30 weeks of treatment","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.7"},{"groupId":"OG001","value":"33.9"}]}]}]},{"type":"SECONDARY","title":"Subjects Who Achieve Weight Loss Above or Equal to 5%","description":"Percentage of subjects who achieved weight loss above or equal to 5% after 30 weeks of treatment. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"After 30 weeks of treatment","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.9"},{"groupId":"OG001","value":"17.7"}]}]}]},{"type":"SECONDARY","title":"Subjects Who Achieve Weight Loss Above or Equal to 10%","description":"Percentage of subjects who achieved weight loss above or equal to 10% after 30 weeks of treatment. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"After 30 weeks of treatment","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.1"},{"groupId":"OG001","value":"4.4"}]}]}]},{"type":"SECONDARY","title":"Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol) Without Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemia Episodes and no Weight Gain","description":"Percentage of subjects who achieved HbA1c below 7.0% (53 mmol/mol) without severe or blood glucose confirmed symptomatic hypoglycaemia episodes and no weight gain, after 30 weeks of treatment. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"After 30 weeks of treatment","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.6"},{"groupId":"OG001","value":"36.8"}]}]}]},{"type":"SECONDARY","title":"Subjects Who Achieve HbA1c Reduction Above or Equal to 1%","description":"Percentage of subjects who achieved weight loss above or equal to 1% after 30 weeks of treatment. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"After 30 weeks of treatment","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.8"},{"groupId":"OG001","value":"48.3"}]}]}]},{"type":"SECONDARY","title":"Subjects Who Achieve HbA1c Reduction Above or Equal to 1% and Weight Loss Above or Equal to 3%","description":"Percentage of subjects who achieved HbA1c reduction above or equal to 1% and weight loss above or equal to 3% after 30 weeks of treatment. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"After 30 weeks of treatment","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.4"},{"groupId":"OG001","value":"20.9"}]}]}]},{"type":"SECONDARY","title":"Subjects Who Achieve HbA1c Reduction Above or Equal to 1% and Weight Loss Above or Equal to 5%","description":"Percentage of subjects who achieved HbA1c reduction above or equal to 1% and weight loss above or equal to 5% after 30 weeks of treatment. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"After 30 weeks of treatment","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.6"},{"groupId":"OG001","value":"11.9"}]}]}]},{"type":"SECONDARY","title":"Subjects Who Achieve HbA1c Reduction Above or Equal to 1% and Weight Loss Above or Equal to 10%","description":"Percentage of subjects who achieved HbA1c reduction above or equal to 1% and weight loss above or equal to 10% after 30 weeks of treatment. Results are based on the on-treatment without rescue medication period. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Full analysis set (FAS), which included all randomised participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"After 30 weeks of treatment","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1"},{"groupId":"OG001","value":"3.6"}]}]}]},{"type":"SECONDARY","title":"Change in SF-36v2 Short Form Health Survey. Total Summary Scores (Physical Component and Mental Component) and Scores From the 8 Domains","description":"Short form-36 version 2 (SF-36v2) is a 36-item patient-reported survey of patient health that measures the subject's overall health-related quality of life (HRQoL). The questionnaire measures the individual overall HRQoL on 8 domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health. Each domain is scored using the sum of the individual item responses and normalised relative to the 2009 US reference population. Overall, the domain scores range from around 0-100 (higher scores indicated a better HRQoL), where the range of possible scores depends on the 2009 US reference population for each domain. The two total summary scores (mental and physical summary components) are calculated through weighted sums of the 8 domain scores. The presented result is the change from baseline (week 0) to week 30 in SF-36v2 scores. A positive change in score indicates an improvement since baseline.","populationDescription":"Full analysis set (FAS), which included all randomised participants. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"scores on a scale","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"title":"Physical functioning","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"5.8"},{"groupId":"OG001","value":"1.4","spread":"6.6"}]}]},{"title":"Role-physical","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"287"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"7.2"},{"groupId":"OG001","value":"0.6","spread":"6.7"}]}]},{"title":"Bodily pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"9.1"},{"groupId":"OG001","value":"1.5","spread":"9.8"}]}]},{"title":"General health","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"7.9"},{"groupId":"OG001","value":"1.6","spread":"7.7"}]}]},{"title":"Social functioning","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"8.7"},{"groupId":"OG001","value":"0.9","spread":"7.7"}]}]},{"title":"Role-emotional","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"287"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"8.5"},{"groupId":"OG001","value":"1.0","spread":"8.0"}]}]},{"title":"Vitality","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"8.0"},{"groupId":"OG001","value":"1.1","spread":"8.0"}]}]},{"title":"Mental health","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"8.2"},{"groupId":"OG001","value":"0.3","spread":"7.2"}]}]},{"title":"Mental component summary","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"287"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"7.9"},{"groupId":"OG001","value":"0.5","spread":"7.5"}]}]},{"title":"Physical component summary","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"287"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"6.4"},{"groupId":"OG001","value":"1.4","spread":"5.9"}]}]}]},{"type":"SECONDARY","title":"Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ). Treatment Satisfaction Summary Score (Sum of 6 of 8 Items) and the 8 Items Separately","description":"The DTSQs questionnaire was used to assess subject's treatment satisfaction. This instrument contains 8 items and measures the treatment for diabetes in terms of convenience, flexibility and general feelings regarding treatment. Q 1 = \"satisfaction with current treatment\"; Q 2 = \"hyperglycemia\"; Q 3 = \"hypoglycemia\"; Q 4 = \"flexibility\"; Q 5 = \"convenience\"; Q 6 = \"understanding of diabetes\"; Q 7 = \"recommend treatment to others\"; and Q 8 = \"willingness to continue\". Each item is rated on a 7-point Likert scale with a score ranging from 0 (ie, very dissatisfied) to 6 (ie, very satisfied). DTSQ items 2 and 3 are rated differently: 0 reflects 'never' and 6 reflects 'most of the time'. The 'treatment satisfaction' score is the sum of 6 of the 8 DTSQs components (Q 1, 4, 5, 6, 7 and 8) (range 0-36). Higher scores on the DTSQ total score indicate higher treatment satisfaction. The results presented is the change from baseline (week 0) to week 30 in DTSQ scores.","populationDescription":"Full analysis set (FAS), which included all randomised participants. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"scores on a scale","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"287"}]}],"classes":[{"title":"Q1. Satisfaction with current treatment","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"286"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.7"},{"groupId":"OG001","value":"0.9","spread":"1.5"}]}]},{"title":"Q2. Hyperglycemia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"286"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"2.1"},{"groupId":"OG001","value":"-1.6","spread":"2.3"}]}]},{"title":"Q3. Hypoglycemia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"286"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.7"},{"groupId":"OG001","value":"0.1","spread":"1.6"}]}]},{"title":"Q4. Flexibility","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"286"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.5"},{"groupId":"OG001","value":"0.6","spread":"1.5"}]}]},{"title":"Q5. Convenience","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"286"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.5"},{"groupId":"OG001","value":"0.6","spread":"1.5"}]}]},{"title":"Q6. Understanding of diabetes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"284"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.4"},{"groupId":"OG001","value":"0.5","spread":"1.3"}]}]},{"title":"Q7. Recommend treatment to others","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"288"},{"groupId":"OG001","value":"286"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.5"},{"groupId":"OG001","value":"0.7","spread":"1.4"}]}]},{"title":"Q8. Willingness to continue","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"285"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.8"},{"groupId":"OG001","value":"0.9","spread":"1.8"}]}]},{"title":"Treatment satisfaction summary score","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"286"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"7.0"},{"groupId":"OG001","value":"4.2","spread":"6.6"}]}]}]},{"type":"SECONDARY","title":"Number of Treatment-emergent Adverse Events (TEAE)","description":"A TEAE was defined as an adverse event with onset date (or increase in severity) during the on-treatment observation period. The on-treatment observation period represents the time period where subjects were considered exposed to trial product.","populationDescription":"Safety analysis set (SAS) included all subjects exposed to at least one dose of trial product. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Events","timeFrame":"Week 0 to week 35","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"758"},{"groupId":"OG001","value":"691"}]}]}]},{"type":"SECONDARY","title":"Number of Treatment-emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes","description":"Hypoglycaemic episodes were defined as treatment emergent if the onset of the episode occurred within the on-treatment observation period, where the subjects were exposed to the trial product. Severe or BG-confirmed symptomatic hypoglycaemia: an episode that was severe according to the ADA classification or blood glucose confirmed by a plasma glucose value below 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.","populationDescription":"Safety analysis set (SAS) included all subjects exposed to at least one dose of trial product. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Episodes of hypoglycaemia","timeFrame":"Week 0 to week 35","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"}]}]}]},{"type":"SECONDARY","title":"Treatment-emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemia Episodes","description":"Number of subjects with treatment-emergent severe or blood glucose confirmed symptomatic hypoglycaemia episodes is presented. Hypoglycaemic episodes were defined as treatment emergent if the onset of the episode occurred within the on-treatment observation period, where the subjects were exposed to the trial product. Severe or BG-confirmed symptomatic hypoglycaemia: an episode that was severe according to the ADA classification or blood glucose confirmed by a plasma glucose value below 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.","populationDescription":"Safety analysis set (SAS) included all subjects exposed to at least one dose of trial product. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Week 0 to week 35","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"}]}]}]},{"type":"SECONDARY","title":"Change in Haematology - Haemoglobin","description":"Mean change from baseline (week 0) to week 30 in haemoglobin. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","populationDescription":"Safety analysis set (SAS) included all subjects exposed to at least one dose of trial product. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"16.0"},{"groupId":"OG001","value":"1.0","spread":"0.0"}]}]}]},{"type":"SECONDARY","title":"Change in Haematology - Haematocrit","description":"Mean change from baseline (week 0) to week 30 in haematology laboratory parameter haematocrit. Haematocrit is the volume of red blood cells in the total blood. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","populationDescription":"Safety analysis set (SAS) included all subjects exposed to at least one dose of trial product. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"percent change","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"111.7"},{"groupId":"OG001","value":"1.1","spread":"130.9"}]}]}]},{"type":"SECONDARY","title":"Change in Haematology - Thrombocytes and Leukocytes","description":"Mean change from baseline (week 0) to week 30 in haematology laboratory parameters thrombocytes and leukocytes. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","populationDescription":"Safety analysis set (SAS) included all subjects exposed to at least one dose of trial product. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"10^9 cells/L","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"287"}]}],"classes":[{"title":"Thrombocytes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"233"},{"groupId":"OG001","value":"245"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","spread":"126.0"},{"groupId":"OG001","value":"21.5","spread":"138.9"}]}]},{"title":"Leukocytes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"287"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"133.2"},{"groupId":"OG001","value":"0.14","spread":"117.3"}]}]}]},{"type":"SECONDARY","title":"Change in Haematology - Erythrocytes","description":"Mean change from baseline (week 0) to week 30 in haematology laboratory parameter erythrocytes. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","populationDescription":"Safety analysis set (SAS) included all subjects exposed to at least one dose of trial product. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"10^12 cells/L","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"133.2"},{"groupId":"OG001","value":"0.14","spread":"117.3"}]}]}]},{"type":"SECONDARY","title":"Change in Biochemistry - Calcium, Pottassium and Sodium","description":"Mean change from baseline (week 0) to week 30 in biochemistry laboratory parameters calcium, pottassium and sodium. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","populationDescription":"Safety analysis set (SAS) included all subjects exposed to at least one dose of trial product. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"287"}]}],"classes":[{"title":"Calcium","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"260"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"107.0"},{"groupId":"OG001","value":"0.07","spread":"103.8"}]}]},{"title":"Pottassium","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"246"},{"groupId":"OG001","value":"260"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"96.0"},{"groupId":"OG001","value":"0.3","spread":"77.3"}]}]},{"title":"Sodium","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"260"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"65.3"},{"groupId":"OG001","value":"1.7","spread":"61.4"}]}]}]},{"type":"SECONDARY","title":"Change in Biochemistry - Alkaline Phosphatase, Alanine Aminotransferase and Aspartate Aminotransferase.","description":"Mean change from baseline (week 0) to week 30 in biochemistry laboratory parameters alkaline phosphatase, alanine aminotransferase and aspartate aminotransferase. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","populationDescription":"Safety analysis set (SAS) included all subjects exposed to at least one dose of trial product. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"287"}]}],"classes":[{"title":"Alkaline phosphatase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"260"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"117.5"},{"groupId":"OG001","value":"6.4","spread":"121.0"}]}]},{"title":"Alanine Aminotransferase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"259"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"126.1"},{"groupId":"OG001","value":"5.0","spread":"137.7"}]}]},{"title":"Aspartate Aminotransferase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"257"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"129.9"},{"groupId":"OG001","value":"3.1","spread":"119.5"}]}]}]},{"type":"SECONDARY","title":"Change in Biochemistry - Amylase and Lipase","description":"Mean change from baseline (week 0) to week 30 in biochemistry laboratory parameters amylase and lypase. Observed data with multiple imputation for missing data is presented. Missing data were imputed using observed data from subjects within the same group defined by actual treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","populationDescription":"Safety analysis set (SAS) included all subjects exposed to at least one dose of trial product. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"U/L","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"287"}]}],"classes":[{"title":"Amylase","categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"124.7"},{"groupId":"OG001","value":"8.4","spread":"138.2"}]}]},{"title":"Lipase","categories":[{"measurements":[{"groupId":"OG000","value":"15.8","spread":"154.6"},{"groupId":"OG001","value":"14.0","spread":"154.5"}]}]}]},{"type":"SECONDARY","title":"Change in Biochemistry - Creatinine and Bilirubin","description":"Mean change from baseline (week 0) to week 30 in biochemistry laboratory parameters creatinine and bilirubin. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","populationDescription":"Safety analysis set (SAS) included all subjects exposed to at least one dose of trial product. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"umol/L","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"287"}]}],"classes":[{"title":"Creatinine","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"260"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"150.2"},{"groupId":"OG001","value":"3.6","spread":"150.0"}]}]},{"title":"Bilirubin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"259"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"167.5"},{"groupId":"OG001","value":"2.0","spread":"126.2"}]}]}]},{"type":"SECONDARY","title":"Change in Biochemistry - Albumin","description":"Mean change from baseline (week 0) to week 30 in biochemistry laboratory parameter albumin. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","populationDescription":"Safety analysis set (SAS) included all subjects exposed to at least one dose of trial product. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"g/dL","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"56.8"},{"groupId":"OG001","value":"0.2","spread":"55.5"}]}]}]},{"type":"SECONDARY","title":"Change in Biochemistry - Estimated Glomerular Filtration Rate (eGFR).","description":"Mean change from baseline (week 0) to week 30 in biochemistry laboratory parameter eGFR. eGFR is calculated using the equation from the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) as defined in KDIGO guidelines. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","populationDescription":"Safety analysis set (SAS) included all subjects exposed to at least one dose of trial product. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"mL/min/1.73m2","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"97.7"},{"groupId":"OG001","value":"4.1","spread":"113.9"}]}]}]},{"type":"SECONDARY","title":"Change in Calcitonin","description":"Mean change from baseline (week 0) to week 30 in calcitonin. Results are based on the on-treatment observation period where subjects were considered exposed to trial product.","populationDescription":"Safety analysis set (SAS) included all subjects exposed to at least one dose of trial product. Number analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ng/L","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"165.5"},{"groupId":"OG001","value":"1.1","spread":"89.7"}]}]}]},{"type":"SECONDARY","title":"Change in Pulse Rate","description":"Mean change from baseline (week 0) to week 30 in pulse rate. Pulse rate is measured as number of heart beats per minute. Results are based on the on-treatment observation period where subjects were considered exposed to trial product. Missing data were imputed using observed data from subjects within the same group defined by randomised treatment, using a regression model including stratification factor as categorical effect and data from baseline and all previous visits as covariates.","populationDescription":"Safety analysis set (SAS) included all subjects exposed to at least one dose of trial product.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"beats/min","timeFrame":"Week 0, week 30","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."},{"id":"OG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"287"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"10.1"},{"groupId":"OG001","value":"3.9","spread":"10.0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From the date of first dose of trial product (week 0) to end of treatment (week 30) + post treatment follow-up of 42 days.","description":"Evaluation of safety was based on safety analysis set (SAS) which comprised of all randomised subjects who received at least one dose of trial product.\n\nAEs with onset during the on-treatment observation period (the period when subjects were exposed to trial product) were considered treatment-emergent.","eventGroups":[{"id":"EG000","title":"Semaglutide 1.0 mg","description":"Subjects received 1.0 mg semaglutide once-weekly for 30 weeks (including 8-week dose escalation period). Semaglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once weekly on the same weekday. Subjects started semaglutide at 0.25 mg and were dose escalated in 4-week increments until the final maintenance dose of 1.0 mg was reached (i.e. 0.25 mg from week 0 to week 4, 0.5 mg from week 4 to week 8 and 1.0 mg from week 8 to week 30). Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these).","deathsNumAffected":0,"deathsNumAtRisk":289,"seriousNumAffected":17,"seriousNumAtRisk":289,"otherNumAffected":139,"otherNumAtRisk":289},{"id":"EG001","title":"Liraglutide 1.2 mg","description":"Subjects received 1.2 mg liraglutide once-daily for 30 weeks (including 1-week dose escalation period). Liraglutide was administered subcutaneously by injections in the thigh, abdomen or upper arm once-daily and the time of injection was to be consistent from one day to another. Subjects started liraglutide at 0.6 mg for 1 week and then were dose escalated to the maintenance dose of 1.2 mg. Subjects also continued their OAD pre-trial background medication (i.e. metformin, SGLT-2 inhibitors, sulphonyl ureas, or combinations of these).","deathsNumAffected":0,"deathsNumAtRisk":287,"seriousNumAffected":22,"seriousNumAtRisk":287,"otherNumAffected":113,"otherNumAtRisk":287}],"seriousEvents":[{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Benign neoplasm of bladder","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":287}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Calculus urinary","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":287}]},{"term":"Cardiovascular examination","organSystem":"Investigations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":287}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":287}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Diabetes mellitus inadequate control","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":287}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Duodenal ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":287}]},{"term":"Facial pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":287}]},{"term":"Hepatic steatosis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":287}]},{"term":"Intervertebral disc disorder","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Leiomyoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":287}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Localised infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Medullary thyroid cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":287}]},{"term":"Menopausal symptoms","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":287}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":287}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":287}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Periarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Prostatic adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Prostatitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":287}]},{"term":"Rectal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":287}]},{"term":"Rectal neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":287}]},{"term":"Retinal vein occlusion","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":287}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Skin ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Umbilical hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":287}]}],"otherEvents":[{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":15,"numAtRisk":289},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":287}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":17,"numAtRisk":289},{"groupId":"EG001","numEvents":13,"numAffected":10,"numAtRisk":287}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":30,"numAtRisk":289},{"groupId":"EG001","numEvents":18,"numAffected":17,"numAtRisk":287}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":56,"numAffected":45,"numAtRisk":289},{"groupId":"EG001","numEvents":43,"numAffected":35,"numAtRisk":287}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":27,"numAtRisk":289},{"groupId":"EG001","numEvents":32,"numAffected":19,"numAtRisk":287}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":9,"numAtRisk":289},{"groupId":"EG001","numEvents":16,"numAffected":15,"numAtRisk":287}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":27,"numAtRisk":289},{"groupId":"EG001","numEvents":32,"numAffected":30,"numAtRisk":287}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":88,"numAffected":62,"numAtRisk":289},{"groupId":"EG001","numEvents":54,"numAffected":45,"numAtRisk":287}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":43,"numAffected":29,"numAtRisk":289},{"groupId":"EG001","numEvents":32,"numAffected":23,"numAtRisk":287}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property."},"pointOfContact":{"title":"Clinical Reporting Anchor and Disclosure (1452)","organization":"Novo Nordisk A/S","email":"clinicaltrials@novonordisk.com","phone":"(+1) 866-867-7178"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2019-05-27","uploadDate":"2019-07-08T08:45","filename":"Prot_000.pdf","size":1715375},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2019-05-27","uploadDate":"2019-07-08T08:45","filename":"SAP_001.pdf","size":415741}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D003924","term":"Diabetes Mellitus, Type 2"}],"ancestors":[{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000591245","term":"semaglutide"},{"id":"D000069450","term":"Liraglutide"}],"ancestors":[{"id":"D052216","term":"Glucagon-Like Peptide 1"},{"id":"D004763","term":"Glucagon-Like Peptides"},{"id":"D052336","term":"Proglucagon"},{"id":"D005768","term":"Gastrointestinal Hormones"},{"id":"D006728","term":"Hormones"},{"id":"D006730","term":"Hormones, Hormone Substitutes, and Hormone Antagonists"}]}},"hasResults":true}